Pharmaceutical - GlaxoSmithKline, Licensing


Current filters:


Popular Filters

1 to 25 of 39 results

Codexis leaps on licensing deal with GlaxoSmithKline

Codexis leaps on licensing deal with GlaxoSmithKline


Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, saw its share…

CodeEvolverCodeEvolver protein engineering platform technologyCodexisGlaxoSmithKlineLicensingPharmaceuticalProductionUK

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1


ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

GlaxoSmithKline divests rights to Treximet to Pernix for $250 million


UK pharma giant GlaxoSmithKline will divest all of its rights to migraine drug Treximet (sumatriptan/naproxen…

GlaxoSmithKlineLicensingNeurologicalPernix TherapeuticsPharmaceuticalPozenTreximetUSA

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines


Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug…

GlaxoSmithKlineLicensingPharmaceuticalSantaris Pharma

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK


UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…


Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline


US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

GlaxoSmithKline returns rights to vercirnon


US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs


US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Briefs: Eddingpharm deal with GSK China for Tykerb; AEterna Zentaris and Ergomed link on AEZS-108


Chinese drugmaker Eddingpharm has entered into a collaboration agreement with UK pharma giant GlaxoSmithKline's…

AEterna ZentarisAEZS-108Asia-PacificErgomed Clinical ResarchGlaxoSmithKlineLicensingOncologyPharmaceuticalResearchTykerb

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir


Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline


BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation


In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

UT MD Anderson signs potentially lucrative deal with GlaxoSmithKline


The University of Texas MD Anderson Cancer Center, one of the world's leading cancer research and treatment…


GlaxoSmithKline gives up on XenoPort Horizant collaboration


UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has reached an agreement with US partner XenoPort…


Milestone payments for Epizyme and Antares Pharma


Privately-held US biotech startup Epizyme says it has received a$4 million in milestone payments from…

Antares PharmaEpizymeFinancialGlaxoSmithKlineLicensingOncologyPfizerPharmaceuticalResearch

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million


US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Research news: dolutegravir; TD-1211; and synaptic modulators


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

1 to 25 of 39 results

Back to top